Discovering a previously unknown genetic condition that affects children, researchers also found a potential method to prevent the gene mutation by administering a drug during pregnancy.
The findings by researchers at the University of California San Diego School of Medicine and Rady Children's Institute for Genomic Medicine were published in The New England Journal of Medicine.
The work involved researchers in Egypt, India, the United Arab Emirates, Brazil and the United States.
"Although different doctors were caring for these children, all of the children showed the same symptoms and all had DNA mutations in the same gene," said senior author Joseph G. Gleeson, MD, Rady Professor of Neuroscience at UC San Diego School of Medicine and director of neuroscience at the Rady Children's Institute for Genomic Medicine.
The research team dubbed the condition "Zaki syndrome" after co-author Maha S. Zaki, MD, PhD, of the National Research Center in Cairo, Egypt, who first spotted the condition. Zaki syndrome affects prenatal development of several organs of the body, including eyes, brain, hands, kidneys and heart. Children suffer from lifelong disabilities. The condition appears to be rare, but future studies are required to determine prevalence.
"We have been perplexed by children with this condition for many years," said Gleeson. "We had observed children around the world with DNA mutations in the Wnt-less (WLS) gene, but did not recognize that they all had the same disease until doctors compared clinical notes. We realized we were dealing with a new syndrome that can be recognized by clinicians, and potentially prevented."
Co-author Bruno Reversade, PhD, a research director at the Agency for Science, Technology and Research (A*STAR) in Singapore, helped identify several families with members suffering from Zaki syndrome and investigate potential therapeutic interventions.
"While we have shown that it's possible to mimic WNT-deficiency with dedicated drugs, the real challenge was to overcome, and possibly rescue, this congenital disease," Reversade said.
Using whole-genome sequencing, researchers documented mutations in the WLS gene, which controls signalling levels for a hormone-like protein known as Wnt (pronounced wint). Wnt signalling is a highly conserved group of protein pathways involved in embryonic development.
The scientists generated stem cells and mouse models for Zaki syndrome and treated the condition with a drug called CHIR99021, which boosts Wnt signalling. In each mouse model, they found CHIR99021 boosted Wnt signals, and restored development. Mouse embryos grew body parts that had been missing and organs resumed normal growth.
"The results were very surprising because it was assumed that structural birth defects like Zaki syndrome could not be prevented with a drug," said first author Guoliang Chai, PhD, a former postdoctoral fellow at UC San Diego School of Medicine now at Capital Medical University in Beijing, China. "We can see this drug, or drugs like it, eventually being used to prevent birth defects, if the babies can be diagnosed early enough."
( With inputs from ANI )
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor